Thursday, November 21, 2024
Subscribe American Journal of Medicine Free Newsletter
Hematologyvenous thromboembolism

venous thromboembolism

What's New from AJM

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with...

0
Frailty predicts poorer outcomes in patients receiving anticoagulation. We assessed the effectiveness and safety of rivaroxaban vs warfarin in frail patients experiencing venous thromboembolism. Methods Using US MarketScan claims data from January 2012-December 2016, we identified frail patients (using the Johns Hopkins Claims-Based Frailty Indicator score) who had ≥1 primary hospitalization/emergency department visit diagnosis codes for venous thromboembolism, received rivaroxaban or...